NEW $i(N)-ARYL AND $i(N)-HETEROARYLUREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A:CHOLESTEROL ACYL TRANSFERASE (ACAT)
申请人:PFIZER INC.
公开号:EP0642498A1
公开(公告)日:1995-03-15
US6001860A
申请人:——
公开号:US6001860A
公开(公告)日:1999-12-14
[EN] NEW N-ARYL AND N-HETEROARYLUREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A:CHOLESTEROL ACYL TRANSFERASE (ACAT)<br/>[FR] NOUVEAU DERIVES N-ARYLE ET DE N-HETEROARYLUREE EN TANT QU'INHIBITEURS DE L'ACYLCOENZIME A: CHOLESTEROL ACYLTRANSFERASE (ACAT)
申请人:PFIZER INC.
公开号:WO1993024458A1
公开(公告)日:1993-12-09
(EN) A compound of formula (I), the pharmaceutically acceptable salts thereof, wherein Q, R17, R18 and R1 are as defined below. The compounds of formula (I) are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.(FR) L'invention concerne un composé représenté par la formule (I) et des sels dérivés pharmaceutiquement acceptables, dans laquelle Q, R17, R18, et R1 ont la même notation que dans le descriptif. Les composés de la formule (I) sont des inhibiteurs de l'acylcoenzyme A: cholesterol acyltransférase (ACAT) et sont utiles en tant qu'agents hypolipidémiants et antiathérosclérose.
N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme
申请人:Pfizer Inc.
公开号:US06001860A1
公开(公告)日:1999-12-14
A compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.17, R.sup.18 and R.sup.1 are as defined below. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.